Considering the fact that (i) PLK1 was the only one of these three identified genes that expression was high in our NSCLC PDXs, (ii) high PLK1 gene expression was the only one of the three tested genes having a pejorative impact on NSCLC patients’ OS, and in order to reverse RAD001 resistance, we then evaluated the in vivo efficacy of only one combination of treatments, i.e., RAD001 plus the PLK1 inhibitor volasertib. Here, PLK1 is linked to non-small cell lung carcinoma.